Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes
| Autor: | Daniel Antonio de Luis Román, Sara Gómez de la Cuesta, Rocío Aller de la Fuente, Carla Tafur, Juan José López Gómez, Natalia Mora Cuadrado, María Concepción García Sánchez, Beatriz Antolín Melero |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty endocrine system diseases Biopsy Endocrinology Diabetes and Metabolism Population 030209 endocrinology & metabolism Type 2 diabetes Severity of Illness Index digestive system Gastroenterology Diabetes Complications 03 medical and health sciences 0302 clinical medicine Endocrinology Non-alcoholic Fatty Liver Disease Internal medicine medicine Humans education education.field_of_study Nutrition and Dietetics medicine.diagnostic_test business.industry Fatty liver nutritional and metabolic diseases Type 2 Diabetes Mellitus Middle Aged medicine.disease digestive system diseases Cross-Sectional Studies Diabetes Mellitus Type 2 Liver biopsy Female 030211 gastroenterology & hepatology Histopathology Steatohepatitis business |
| Zdroj: | Endocrinología, Diabetes y Nutrición (English ed.). 65:354-360 |
| ISSN: | 2530-0180 |
| Popis: | Prevalence of non-alcoholic fatty liver disease (NAFLD) in developed countries is 30% in the general population and 50% in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to compare the severity of NAFLD, as assessed by liver biopsy and using the non-invasive index NAFLD Fibrosis Score (NFS), in subjects with and without T2DM.The study sample consisted of 217 patients with biopsy-proven NAFLD. Anthropometric assessments, laboratory tests, histological criteria established by the Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN), and the NFS were recorded.Patients with T2DM (n=36; 16.5%) had higher HOMA-IR values (6.3±3.6 vs. 3.3±2.4; p0.0001), GGT levels (125.2±102.3 vs. 82.5±70.6IU/l; p005), and NFS index (-0.6±0.2 vs. -1.8±0.1; p0.001) than subjects with no T2DM. Patients with T2DM were found higher rates of NASH (72.2% vs. 48.6%; p0.05), advanced steatosis (80.6% vs. 63%; p0.05), and liver fibrosis (75% vs. 43.1%, p0.05) than patients with no T2DM. Patients with T2DM also had higher NFS values (-0.6±1.2 vs. -1.8±1.8: p=0.01). A logistic regression analysis adjusting for age, gender and BMI showed a significant independent association between NASH and presence of T2DM (OR=4.2: 95% CI: 1.4-12.1; p=0.007). A second model adjusting for the same covariates showed T2DM to be an independent factor associated to advanced fibrosis (OR=4.1; 95% CI: 1.7-9.7).Patients with T2DM have more advanced degrees of NAFLD and advanced fibrosis as assessed by liver biopsy and the NFS index. Particular attention should be paid to the study and monitoring of NASH in patients with T2DM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect